Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Christine Lin, Kimberly R Ballinger & Salman R Khetani. (2015) The application of engineered liver tissues for novel drug discovery. Expert Opinion on Drug Discovery 10:5, pages 519-540.
Read now
Read now
Mark J Canet & Nathan J Cherrington. (2014) Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis. Expert Opinion on Drug Metabolism & Toxicology 10:9, pages 1209-1219.
Read now
Read now
Vasilios G. Athyros, Konstantinos Tziomalos, Georgios N. Daskalopoulos, Asterios Karagiannis & Dimitri P. Mikhailidis. (2011) Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. Annals of Medicine 43:3, pages 167-171.
Read now
Read now
Articles from other publishers (79)
Parisa Sadighara, Amir Hossein Abedini, Namra Irshad, Mahmoud Ghazi-Khansari, Ali Esrafili & Mahmood Yousefi. (2023) Association Between Non-alcoholic Fatty Liver Disease and Heavy Metal Exposure: a Systematic Review. Biological Trace Element Research 201:12, pages 5607-5615.
Crossref
Crossref
Rosaria Maria Pipitone, Rossella Zito, Giuditta Gambino, Gabriele Di Maria, Ayesha Javed, Giulia Lupo, Giuseppe Giglia, Pierangelo Sardo, Giuseppe Ferraro, Francesca Rappa, Daniela Carlisi, Danila Di Majo & Stefania Grimaudo. (2023) Red and golden tomato administration improves fat diet-induced hepatic steatosis in rats by modulating HNF4α, Lepr, and GK expression. Frontiers in Nutrition 10.
Crossref
Crossref
Zahra Safari, Mohammad Bagherniya, Ziba Khoram, Amrollah Ebrahimi Varzaneh, Zahra Heidari, Amirhossein Sahebkar & Gholamreza Askari. (2023) The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers. Frontiers in Nutrition 10.
Crossref
Crossref
Shreyoshi Guha, Selvam Sesili, Ishfaq Hassan Mir & Chinnasamy Thirunavukkarasu. (2022) Epigenetics and mitochondrial dysfunction insights into the impact of the progression of non‐alcoholic fatty liver disease. Cell Biochemistry and Function 41:1, pages 4-19.
Crossref
Crossref
Laura Guerrero, Alberto Paradela & Fernando J. Corrales. (2022) Targeted Proteomics for Monitoring One-Carbon Metabolism in Liver Diseases. Metabolites 12:9, pages 779.
Crossref
Crossref
Huan Yi, Hengyang Peng, Xinyue Wu, Xinmei Xu, Tingting Kuang, Jing Zhang, Leilei Du & Gang Fan. (2021) The Therapeutic Effects and Mechanisms of Quercetin on Metabolic Diseases: Pharmacological Data and Clinical Evidence. Oxidative Medicine and Cellular Longevity 2021, pages 1-16.
Crossref
Crossref
Xiong‐Zhang Yin, Wei‐Ming Chi, Ling Zhang, Yan‐Qi Su, Zhong‐Yuan Zhang & Cheng‐Bin Xue. (2021)
Protective effects of
Dendrobium candidum
Wall ex Lindl. on high‐fat diet‐induced liver damage in mice
. Journal of Food Biochemistry 45:4.
Crossref
Crossref
Christopher Crabtree, Madison Kackley, Alexandru Buga, Brandon Fell, Richard LaFountain, Parker Hyde, Teryn Sapper, William Kraemer, Debbie Scandling, Orlando Simonetti & Jeff Volek. (2021) Comparison of Ketogenic Diets with and without Ketone Salts versus a Low-Fat Diet: Liver Fat Responses in Overweight Adults. Nutrients 13:3, pages 966.
Crossref
Crossref
Fatemeh Naeini, Zahra Namkhah, Alireza Ostadrahimi, Helda Tutunchi & Mohammad Javad Hosseinzadeh-Attar. (2021) A Comprehensive Systematic Review of the Effects of Naringenin, a Citrus-Derived Flavonoid, on Risk Factors for Nonalcoholic Fatty Liver Disease. Advances in Nutrition 12:2, pages 413-428.
Crossref
Crossref
Ahmet AKTAŞ & Zeynep OZAN. (2020) THE EFFICACY AND SAFETY OF VILDAGLIPTIN TREATMENT FOR NONALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES MELLITUS. Cumhuriyet Medical Journal.
Crossref
Crossref
Takeo Minamikawa, Mayuko Ichimura-Shimizu, Hiroki Takanari, Yuki Morimoto, Ryosuke Shiomi, Hiroki Tanioka, Eiji Hase, Takeshi Yasui & Koichi Tsuneyama. (2020) Molecular imaging analysis of microvesicular and macrovesicular lipid droplets in non-alcoholic fatty liver disease by Raman microscopy. Scientific Reports 10:1.
Crossref
Crossref
Po-An Hu, Chia-Hui Chen, Bei-Chia Guo, Yu Ru Kou & Tzong-Shyuan Lee. (2020) Bromelain Confers Protection Against the Non-Alcoholic Fatty Liver Disease in Male C57BL/6 Mice. Nutrients 12:5, pages 1458.
Crossref
Crossref
April D. Lake, Rhiannon N. Hardwick, Christopher P. Leamon, Philip S. Low & Nathan J. Cherrington. (2019) Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis. Toxicology and Applied Pharmacology 368, pages 49-54.
Crossref
Crossref
Maggie A Stanislawski, Catherine A Lozupone, Brandie D Wagner, Merete Eggesbø, Marci K Sontag, Nichole M Nusbacher, Mercedes Martinez & Dana Dabelea. (2018) Gut microbiota in adolescents and the association with fatty liver: the EPOCH study. Pediatric Research 84:2, pages 219-227.
Crossref
Crossref
Yuhei Aotani, Yuta Kumagai, Masanobu Kameda, Kenji Wada, Toshiyuki Matsunaka, Hiroyasu Morikawa & Hiromichi Horinaka. (2018) Improvement of a combined ultrasonic probe used in ultrasonic velocity-change method for evaluation of fat content. Japanese Journal of Applied Physics 57:7S1, pages 07LF18.
Crossref
Crossref
Nilay Thakkar, Jason R. Slizgi & Kim L.R. Brouwer. (2017) Effect of Liver Disease on Hepatic Transporter Expression and Function. Journal of Pharmaceutical Sciences 106:9, pages 2282-2294.
Crossref
Crossref
John D. Clarke, Petr Novak, April D. Lake, Rhiannon N. Hardwick & Nathan J. Cherrington. (2017) Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. Liver International 37:7, pages 1074-1081.
Crossref
Crossref
Youying Zhang, Tian Meng, Ling Zuo, Yu Bei, Qihao Zhang, Zhijian Su, Yadong Huang, Jiyan Pang, Qi Xiang & Hongtu Yang. (2017) Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models. Marine Drugs 15:6, pages 163.
Crossref
Crossref
JianHua Han, Anika L. Dzierlenga, Zhengqiang Lu, Dean D. Billheimer, Elmira Torabzadeh, April D. Lake, Hui Li, Petr Novak, Petia Shipkova, Nelly Aranibar, Donald Robertson, Michael D. Reily, Lois D. Lehman-McKeeman & Nathan J. Cherrington. (2017) Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model. Obesity 25:6, pages 1069-1076.
Crossref
Crossref
Erenius Toppo, S. Sylvester Darvin, S. Esakkimuthu, A. Stalin, K. Balakrishna, K. Sivasankaran, P. Pandikumar, S. Ignacimuthu & N.A. Al-Dhabi. (2017) Antihyperlipidemic and hepatoprotective effects of Gardenin A in cellular and high fat diet fed rodent models. Chemico-Biological Interactions 269, pages 9-17.
Crossref
Crossref
H. Morikawa, K. Mano, H. Horinaka, T. Matsunaka, Y. Matsumoto, T. Ida, Y. Kawaguchi, K. Wada & N. Kawada. (2016) Development of non-invasive method for assessment of hepatic steatosis. Ultrasonics 72, pages 195-200.
Crossref
Crossref
April D. Lake, Alexandria L. Chaput, Petr Novak, Nathan J. Cherrington & Catharine L. Smith. (2016) Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis. Biochemical Pharmacology 122, pages 62-71.
Crossref
Crossref
Sudipa Sarkar, James G. Terry, T. Alp Ikizler, John R. CrouseIIIIII, J. Jeffrey Carr & Adriana M. Hung. (2016) The effect of high intensity statin use on liver density: A post hoc analysis of the coronary artery calcification treatment with zocor [CATZ] study. Obesity Research & Clinical Practice 10:5, pages 613-615.
Crossref
Crossref
Amandla Atilano-Roque, Gavriel Roda, Uma Fogueri, Jennifer J. Kiser & Melanie S. Joy. (2016) Effect of Disease Pathologies on Transporter Expression and Function. The Journal of Clinical Pharmacology 56, pages S205-S221.
Crossref
Crossref
Yaofeng Cheng, Ayman El-Kattan, Yan Zhang, Adrian S. Ray & Yurong Lai. (2016) Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development. Chemical Research in Toxicology 29:4, pages 545-563.
Crossref
Crossref
Mingxing Yang, Xiumin Li, Xin Zeng, Zhimin Ou, Mei Xue, Dehong Gao, Suhuan Liu, Xuejun Li & Shuyu Yang. (2016)
Rheum palmatum
L. Attenuates High Fat Diet-Induced Hepatosteatosis by Activating AMP-Activated Protein Kinase
. The American Journal of Chinese Medicine 44:03, pages 551-564.
Crossref
Crossref
M. ZAGOROVA, A. PRASNICKA, Z. KADOVA, E. DOLEZELOVA, L. KAZDOVA, J. CERMANOVA, L. ROZKYDALOVA, M. HROCH, J. MOKRY & S. MICUDA. (2015) Boldine Attenuates Cholestasis Associated With Nonalcoholic Fatty Liver Disease in Hereditary Hypertriglyceridemic Rats Fed by High-Sucrose Diet. Physiological Research, pages S467-S476.
Crossref
Crossref
Jie Ming, Shaoyong Xu, Bin Gao, Guocai Liu, Yufei Ji, Fan Yang, Yunan Jia, Yujie Fang & Qiuhe Ji. (2015) Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study. Liver International 35:11, pages 2401-2407.
Crossref
Crossref
John D. Clarke, Anika L. Dzierlenga, Nicholas R. Nelson, Hui Li, Samantha Werts, Michael J. Goedken & Nathan J. Cherrington. (2015) Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. Diabetes 64:9, pages 3305-3313.
Crossref
Crossref
Helen M. Parker, Helen T. O’Connor, Shelley E. Keating, Jeffrey S. Cohn, Manohar L. Garg, Ian D. Caterson, Jacob George & Nathan A. Johnson. (2015) Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study. British Journal of Nutrition 114:05, pages 780-787.
Crossref
Crossref
John D. Clarke & Nathan J. Cherrington. (2015) Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Pharmacology & Therapeutics 151, pages 99-106.
Crossref
Crossref
April D. Lake, Petr Novak, Petia Shipkova, Nelly Aranibar, Donald G. Robertson, Michael D. Reily, Lois D. Lehman-McKeeman, Richard R. Vaillancourt & Nathan J. Cherrington. (2014) Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids 47:3, pages 603-615.
Crossref
Crossref
Mark J. Canet, Rhiannon N. Hardwick, April D. Lake, Anika L. Dzierlenga, John D. Clarke, Michael J. Goedken & Nathan J. Cherrington. (2015) Renal Xenobiotic Transporter Expression is Altered in Multiple Experimental Models of Nonalcoholic Steatohepatitis. Drug Metabolism and Disposition 43:2, pages 266-272.
Crossref
Crossref
John D. Clarke, Rhiannon N. Hardwick, April D. Lake, Andrew J. Lickteig, Michael J. Goedken, Curtis D. Klaassen & Nathan J. Cherrington. (2014) Synergistic interaction between genetics and disease on pravastatin disposition. Journal of Hepatology 61:1, pages 139-147.
Crossref
Crossref
Benjamin Udoka Nwosu & Louise Maranda. (2014) The Effects of Vitamin D Supplementation on Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Children and Adolescents with Vitamin D Deficiency and Either Type 1 or Type 2 Diabetes Mellitus. PLoS ONE 9:6, pages e99646.
Crossref
Crossref
Hwa-Li Tan, Shamsul Mohd Zain, Rosmawati Mohamed, Sanjay Rampal, Kin-Fah Chin, Roma Choudhury Basu, Phaik-Leng Cheah, Sanjiv Mahadeva & Zahurin Mohamed. (2013) Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. Journal of Gastroenterology 49:6, pages 1056-1064.
Crossref
Crossref
John D. Clarke, Tatiana Sharapova, April D. Lake, Eric Blomme, Jonathan Maher & Nathan J. Cherrington. (2014) Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. Journal of Applied Toxicology 34:6, pages 726-732.
Crossref
Crossref
Mark J. Canet, Rhiannon N. Hardwick, April D. Lake, Anika L. Dzierlenga, John D. Clarke & Nathan J. Cherrington. (2014) Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models. Drug Metabolism and Disposition 42:4, pages 586-595.
Crossref
Crossref
John D. Clarke, Rhiannon N. Hardwick, April D. Lake, Mark J. Canet & Nathan J. Cherrington. (2014) Experimental Nonalcoholic Steatohepatitis Increases Exposure to Simvastatin Hydroxy Acid by Decreasing Hepatic Organic Anion Transporting Polypeptide Expression. Journal of Pharmacology and Experimental Therapeutics 348:3, pages 452-458.
Crossref
Crossref
John D. Clarke, Petr Novak, April D. Lake, Petia Shipkova, Nelly Aranibar, Donald Robertson, Paul L. Severson, Michael D. Reily, Bernard W. Futscher, Lois D. Lehman-McKeeman & Nathan J. Cherrington. (2013) Characterization of Hepatocellular Carcinoma Related Genes and Metabolites in Human Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences 59:2, pages 365-374.
Crossref
Crossref
April D. Lake, Petr Novak, Rhiannon N. Hardwick, Brieanna Flores-Keown, Fei Zhao, Walter T. Klimecki & Nathan J. Cherrington. (2014) The Adaptive Endoplasmic Reticulum Stress Response to Lipotoxicity in Progressive Human Nonalcoholic Fatty Liver Disease. Toxicological Sciences 137:1, pages 26-35.
Crossref
Crossref
Hui Fan, QingRong Pan, Yuan Xu & XinChun Yang. (2013) Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arquivos Brasileiros de Endocrinologia & Metabologia 57:9, pages 702-708.
Crossref
Crossref
Xin Gao & Jian‐Gao Fan. (2013)
Diagnosis and management of non‐alcoholic fatty liver disease and related metabolic disorders: Consensus statement from the
S
tudy
G
roup of
L
iver and
M
etabolism,
C
hinese
S
ociety of
E
ndocrinology (非酒精性脂肪性肝病与相关代谢紊乱诊疗共识——中华医学会内分泌学分会肝病与代谢学组)
. Journal of Diabetes 5:4, pages 406-415.
Crossref
Crossref
April D. Lake, Petr Novak, Petia Shipkova, Nelly Aranibar, Donald Robertson, Michael D. Reily, Zhenqiang Lu, Lois D. Lehman-McKeeman & Nathan J. Cherrington. (2013) Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicology and Applied Pharmacology 268:2, pages 132-140.
Crossref
Crossref
Rhiannon N. Hardwick, Daniel W. Ferreira, Vijay R. More, April D. Lake, Zhenqiang Lu, Jose E. Manautou, Angela L. Slitt & Nathan J. Cherrington. (2013) Altered UDP-Glucuronosyltransferase and Sulfotransferase Expression and Function during Progressive Stages of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition 41:3, pages 554-561.
Crossref
Crossref
K. H. Williams, N. A. Shackel, M. D. Gorrell, S. V. McLennan & S. M. Twigg. (2013) Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo. Endocrine Reviews 34:1, pages 84-129.
Crossref
Crossref
J. Shen, H. L.-Y. Chan, G. L.-H. Wong, A. W.-H. Chan, P. C.-L. Choi, H.-Y. Chan, A. M.-L. Chim, D. K.-W. Yeung, J. Yu, W. C.-W. Chu & V. W.-S. Wong. (2012) Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary Pharmacology & Therapeutics 36:11-12, pages 1057-1066.
Crossref
Crossref
C. M. Hoyos, B. J. Yee, C. L. Phillips, E. A. Machan, R. R. Grunstein & P. Y. Liu. (2012) Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. European Journal of Endocrinology 167:4, pages 531-541.
Crossref
Crossref
Mark J. Canet, Rhiannon N. Hardwick, April D. Lake, Michael J. Kopplin, George L. Scheffer, Walter T. Klimecki, A. Jay Gandolfi & Nathan J. Cherrington. (2012) Altered Arsenic Disposition in Experimental Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition 40:9, pages 1817-1824.
Crossref
Crossref
Yusuf Yilmaz. (2012) Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. Clinica Chimica Acta 413:15-16, pages 1190-1193.
Crossref
Crossref
Jiayun Shen, Henry Lik-Yuen Chan, Grace Lai-Hung Wong, Paul Cheung-Lung Choi, Anthony Wing-Hung Chan, Hoi-Yun Chan, Angel Mei-Ling Chim, David Ka-Wai Yeung, Francis Ka-Leung Chan, Jean Woo, Jun Yu, Winnie Chiu-Wing Chu & Vincent Wai-Sun Wong. (2012) Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. Journal of Hepatology 56:6, pages 1363-1370.
Crossref
Crossref
Rhiannon N. Hardwick & Nathan J. Cherrington. (2012) Measuring Altered Disposition of Xenobiotics in Experimental Models of Liver Disease. Current Protocols in Toxicology 52:1.
Crossref
Crossref
Kenneth Cusi. (2012) Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. Gastroenterology 142:4, pages 711-725.e6.
Crossref
Crossref
Rhiannon N. Hardwick, Craig D. Fisher, Stephanie M. Street, Mark J. Canet & Nathan J. Cherrington. (2012) Molecular Mechanism of Altered Ezetimibe Disposition in Nonalcoholic Steatohepatitis. Drug Metabolism and Disposition 40:3, pages 450-460.
Crossref
Crossref
Byoung C. MoonAntonio Hernandez-OnoBangyan StilesHong WuHenry N. Ginsberg. (2012) Apolipoprotein B Secretion Is Regulated by Hepatic Triglyceride, and Not Insulin, in a Model of Increased Hepatic Insulin Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology 32:2, pages 236-246.
Crossref
Crossref
Rhiannon N. Hardwick, Craig D. Fisher, Mark J. Canet, George L. Scheffer & Nathan J. Cherrington. (2011) Variations in ATP-Binding Cassette Transporter Regulation during the Progression of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition 39:12, pages 2395-2402.
Crossref
Crossref
Romina Lomonaco, Janet Chen & Kenneth Cusi. (2011) An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Therapeutic Advances in Endocrinology and Metabolism 2:5, pages 211-225.
Crossref
Crossref
April D. Lake, Petr Novak, Craig D. Fisher, Jonathan P. Jackson, Rhiannon N. Hardwick, D. Dean Billheimer, Walter T. Klimecki & Nathan J. Cherrington. (2011) Analysis of Global and Absorption, Distribution, Metabolism, and Elimination Gene Expression in the Progressive Stages of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition 39:10, pages 1954-1960.
Crossref
Crossref
Gianluca Svegliati-Baroni, Stefania Saccomanno, Chiara Rychlicki, Laura Agostinelli, Samuele De Minicis, Cinzia Candelaresi, Graziella Faraci, Deborah Pacetti, Marco Vivarelli, Daniele Nicolini, Paolo Garelli, Alessandro Casini, Melania Manco, Geltrude Mingrone, Andrea Risaliti, Giuseppe N. Frega, Antonio Benedetti & Amalia Gastaldelli. (2011) Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver International 31:9, pages 1285-1297.
Crossref
Crossref
. (2011) Focus on Type 2 Diabetes Comorbidities. Endocrine Practice 17:Supplement 5, pages 1-30.
Crossref
Crossref
Kenneth Cusi. (2011) Focus on the Type 2 Diabetes Patient with Liver Disease: Emphasis on Nonalcoholic Fatty Liver Disease (NAFLD). Endocrine Practice 17, pages 9-13.
Crossref
Crossref
Shaoyun Wang, Amrita Kamat, Pablo Pergola, Anita Swamy, Fermin Tio & Kenneth Cusi. (2011) Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo. Metabolism 60:8, pages 1090-1099.
Crossref
Crossref
Simona Moscatiello, Raffaella Di Luzio, Elisabetta Bugianesi, Alessandro Suppini, Ingrid J. Hickman, Silvia Di Domizio, Riccardo Dalle Grave & Giulio Marchesini. (2012) Cognitive‐Behavioral Treatment of Nonalcoholic Fatty Liver Disease: A Propensity Score‐Adjusted Observational Study. Obesity 19:4, pages 763-770.
Crossref
Crossref
Jian Gao FAN, Ji Dong JIA, You Ming LI, Bing Yuan WANG, Lun Gen LU, Jun Pin SHI & Lik Yuen CHAN. (2011) Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. Journal of Digestive Diseases 12:1, pages 38-44.
Crossref
Crossref
Albert J. Czaja. (2010) Performance Parameters of the Conventional Serological Markers for Autoimmune Hepatitis. Digestive Diseases and Sciences 56:2, pages 545-554.
Crossref
Crossref
Yara Haddad, Diane Vallerand, Antoine Brault, Jean Sp?nard & Pierre S. Haddad. (2011) NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA. International Journal of Hepatology 2011, pages 1-12.
Crossref
Crossref
Carolina Ortiz-Lopez, Maria L Policarpio-Nicolas & Kenneth Cusi. (2011) Effect of pioglitazone in a patient with impaired glucose tolerance and nonalcoholic steatohepatitis. Diabetes Management 1:1, pages 33-36.
Crossref
Crossref
J.-F. Blickl?. (2011) Traitement du diab?te en dehors de l'insuline. EMC - Endocrinologie - Nutrition 8:1, pages 1-20.
Crossref
Crossref
Rhiannon N. Hardwick, Craig D. Fisher, Mark J. Canet, April D. Lake & Nathan J. Cherrington. (2010) Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition 38:12, pages 2293-2301.
Crossref
Crossref
Bharat B. Aggarwal. (2010) Targeting Inflammation-Induced Obesity and Metabolic Diseases by Curcumin and Other Nutraceuticals. Annual Review of Nutrition 30:1, pages 173-199.
Crossref
Crossref
Anna Alisi, Mattia Locatelli & Valerio Nobili. (2010) Nonalcoholic fatty liver disease in children. Current Opinion in Clinical Nutrition and Metabolic Care 13:4, pages 397-402.
Crossref
Crossref
Sandhya Narasimhan, Kuppan Gokulakrishnan, Rangasamy Sampathkumar, Syed Farooq, Radhakrishnan Ravikumar, Viswanathan Mohan & Muthuswamy Balasubramanyam. (2010) Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clinical Biochemistry 43:10-11, pages 815-821.
Crossref
Crossref
M Arrese & S J Karpen. (2010) Nuclear Receptors, Inflammation, and Liver Disease: Insights for Cholestatic and Fatty Liver Diseases. Clinical Pharmacology & Therapeutics 87:4, pages 473-478.
Crossref
Crossref
W. Stremmel, A. Pathil-Warth & W. Chamulitrat. (2010) Neue Aspekte zur Pathogenese der NASHNew aspects in the pathogenesis of NASH. Der Gastroenterologe 5:2, pages 101-107.
Crossref
Crossref
U. Schempf, U.M. Lauer, M. Gregor & M. Bitzer. (2010) NASH – eine ungelöste therapeutische HerausforderungNASH – an unresolved therapeutic challenge. Der Gastroenterologe 5:2, pages 123-128.
Crossref
Crossref
Sarah M. Lindbäck, Charles Gabbert, Benjamin L. Johnson, Emmanuil Smorodinsky, Claude B. Sirlin, Natalie Garcia, Perrie E. Pardee, Kristin D. Kistler & Jeffrey B. Schwimmer. (2010) Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics 57:1, pages 85-140.
Crossref
Crossref
Kenneth Cusi. (2009) Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 13:4, pages 545-563.
Crossref
Crossref
Amalia Gastaldelli, Stephen A. Harrison, Renata Belfort-Aguilar, Lou Jean Hardies, Bogdan Balas, Steven Schenker & Kenneth Cusi. (2009) Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50:4, pages 1087-1093.
Crossref
Crossref
M. Contestin & J.-L. Wemeau. (2009) Obésité, stéatose et insulinorésistance. D’après le Symposium III, Congrès de l’ALFEDIAM, Bruxelles, 27 mars 2008. Annales d'Endocrinologie 70:4, pages 262-263.
Crossref
Crossref